Soleno Therapeutics (NASDAQ:SLNO) Price Target Cut to $80.00 by Analysts at Oppenheimer

Soleno Therapeutics (NASDAQ:SLNO) had its price target reduced by Oppenheimer from $110.00 to $80.00 in a research report sent to investors on Wednesday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other research analysts have also weighed in on SLNO. TD Cowen dropped their price target on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Zacks Research lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Wolfe Research set a $60.00 target price on Soleno Therapeutics in a report on Monday, January 12th. Finally, HC Wainwright decreased their price target on Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $104.54.

Soleno Therapeutics Trading Down 2.4%

NASDAQ SLNO opened at $32.80 on Wednesday. The firm has a market capitalization of $1.69 billion, a P/E ratio of 142.61 and a beta of -3.16. The business has a fifty day simple moving average of $40.02 and a 200 day simple moving average of $50.32. Soleno Therapeutics has a 12 month low of $32.15 and a 12 month high of $90.32. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. On average, analysts predict that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SLNO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Soleno Therapeutics by 1.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after purchasing an additional 189 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Soleno Therapeutics in the 2nd quarter worth approximately $25,000. Avanza Fonder AB lifted its stake in Soleno Therapeutics by 11.2% in the fourth quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock valued at $148,000 after purchasing an additional 323 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Soleno Therapeutics by 11.9% in the third quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock valued at $216,000 after purchasing an additional 340 shares during the last quarter. Finally, New York State Common Retirement Fund grew its holdings in Soleno Therapeutics by 2.4% during the third quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock valued at $1,055,000 after purchasing an additional 360 shares during the period. 97.42% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Neutral Sentiment: Oppenheimer lowered its price target on SLNO from $110 to $80 but kept an “Outperform” rating, signaling the analyst still sees significant upside versus current levels while dialing back assumptions. Oppenheimer price target cut
• Negative Sentiment: Multiple law firms have filed or announced investor alerts about a securities class action alleging material misstatements/omissions related to Soleno’s Phase 3 clinical program for DCCR (VYKAT™ XR) and reported launch disruptions. Firms publicly soliciting clients and lead‑plaintiff applicants include Kessler Topaz, Hagens Berman, Levi & Korsinsky, Frank R. Cruz, Robbins Geller, Faruqi & Faruqi, Rosen, Kahn Swick & Foti, Glancy Prongay, Schall, Bernstein Liebhard and others. These filings raise the prospect of litigation costs, potential damages, management distraction and reputational harm that can pressure the stock; the lead‑plaintiff deadline cited in many notices is May 5, 2026. Kessler Topaz investor alert

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.